Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000704319 | Skin | AK | cell-cell junction assembly | 36/1910 | 146/18723 | 3.88e-07 | 1.47e-05 | 36 |
GO:006145820 | Skin | AK | reproductive system development | 77/1910 | 427/18723 | 4.76e-07 | 1.74e-05 | 77 |
GO:190165425 | Skin | AK | response to ketone | 43/1910 | 194/18723 | 7.32e-07 | 2.49e-05 | 43 |
GO:000756826 | Skin | AK | aging | 63/1910 | 339/18723 | 1.83e-06 | 5.42e-05 | 63 |
GO:003196025 | Skin | AK | response to corticosteroid | 37/1910 | 167/18723 | 4.28e-06 | 1.05e-04 | 37 |
GO:000189020 | Skin | AK | placenta development | 33/1910 | 144/18723 | 6.49e-06 | 1.47e-04 | 33 |
GO:005138425 | Skin | AK | response to glucocorticoid | 33/1910 | 148/18723 | 1.20e-05 | 2.46e-04 | 33 |
GO:003459927 | Skin | AK | cellular response to oxidative stress | 53/1910 | 288/18723 | 1.56e-05 | 3.05e-04 | 53 |
GO:004343425 | Skin | AK | response to peptide hormone | 69/1910 | 414/18723 | 2.87e-05 | 4.98e-04 | 69 |
GO:007137517 | Skin | AK | cellular response to peptide hormone stimulus | 52/1910 | 290/18723 | 3.86e-05 | 6.35e-04 | 52 |
GO:00325709 | Skin | AK | response to progesterone | 13/1910 | 37/18723 | 4.21e-05 | 6.70e-04 | 13 |
GO:190165320 | Skin | AK | cellular response to peptide | 61/1910 | 359/18723 | 4.60e-05 | 7.21e-04 | 61 |
GO:003235510 | Skin | AK | response to estradiol | 30/1910 | 141/18723 | 7.41e-05 | 1.06e-03 | 30 |
GO:007138510 | Skin | AK | cellular response to glucocorticoid stimulus | 16/1910 | 56/18723 | 1.02e-04 | 1.34e-03 | 16 |
GO:007138410 | Skin | AK | cellular response to corticosteroid stimulus | 16/1910 | 61/18723 | 3.03e-04 | 3.12e-03 | 16 |
GO:00715497 | Skin | AK | cellular response to dexamethasone stimulus | 10/1910 | 29/18723 | 3.86e-04 | 3.70e-03 | 10 |
GO:003249620 | Skin | AK | response to lipopolysaccharide | 55/1910 | 343/18723 | 4.79e-04 | 4.44e-03 | 55 |
GO:00106448 | Skin | AK | cell communication by electrical coupling | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
GO:00325262 | Skin | AK | response to retinoic acid | 22/1910 | 107/18723 | 1.04e-03 | 8.17e-03 | 22 |
GO:00075658 | Skin | AK | female pregnancy | 34/1910 | 193/18723 | 1.09e-03 | 8.48e-03 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GJB2 | SNV | Missense_Mutation | | c.438N>G | p.Phe146Leu | p.F146L | P29033 | protein_coding | tolerated(0.16) | benign(0.187) | TCGA-A1-A0SJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | | c.599G>T | p.Gly200Val | p.G200V | P29033 | protein_coding | tolerated(0.52) | benign(0.044) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | rs80338950 | c.551G>A | p.Arg184Gln | p.R184Q | P29033 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GJB2 | insertion | Frame_Shift_Ins | novel | c.671dupA | p.Pro225AlafsTer32 | p.P225Afs*32 | P29033 | protein_coding | | | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | rs376898963 | c.493N>T | p.Arg165Trp | p.R165W | P29033 | protein_coding | tolerated(0.07) | benign(0.246) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | novel | c.25N>G | p.Ile9Val | p.I9V | P29033 | protein_coding | tolerated(0.24) | benign(0) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
GJB2 | SNV | Missense_Mutation | novel | c.48N>A | p.His16Gln | p.H16Q | P29033 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | rs104894401 | c.428N>A | p.Arg143Gln | p.R143Q | P29033 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AJ-A3NG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | | c.31G>A | p.Gly11Arg | p.G11R | P29033 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GJB2 | SNV | Missense_Mutation | | c.450N>A | p.Phe150Leu | p.F150L | P29033 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |